Johnson & Johnson announced its third‑quarter 2025 results on Thursday, reporting revenue of $23.99 billion, up 6.8% year‑over‑year, and adjusted earnings per share of $2.80, beating expectations.
Operational sales grew 5.4% and adjusted operational growth was 4.4%, driven by strong performance in its Innovative Medicine and MedTech segments.
The company raised its full‑year 2025 sales outlook to $93.5 billion to $93.9 billion and adjusted EPS guidance to $10.80 to $10.90, reflecting confidence in continued growth.
The earnings beat and guidance raise reinforce J&J’s resilience amid headwinds such as the loss of exclusivity for Stelara and ongoing talc litigation, underscoring the company’s diversified portfolio and robust cash flow generation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.